Physician profile
Amie Jackson
NPI 1023246949
$1,031.38
in general payments reported to CMS, 2019-2025
15 companies · $348 in 2025
The $348 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $45.08 · 2024: $639 · 2025: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $579 · Grant: $350 · Education: $57.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $578.64 |
| Grant | $350.00 |
| Education | $57.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $407.66 | 2024 | Enhertu |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $249.86 | 2024-2025 | Caplyta |
| Daiichi Sankyo INC. | $72.12 | 2024-2025 | Enhertu, Injectafer |
| Merck Sharp & Dohme LLC | $67.70 | 2024-2025 | Keytruda, Lynparza |
| Eisai INC. | $32.19 | 2025 | |
| Abbvie INC. | $31.78 | 2025 | |
| Pfizer INC. | $27.32 | 2025 | |
| Alkermes, INC. | $22.98 | 2025 | Vivitrol |
| Agios Pharmaceuticals, INC. | $22.93 | 2025 | Pyrukynd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.23 | 2025 | |
| Kyowa Kirin, INC. | $17.44 | 2021 | |
| Stemline Therapeutics INC. | $16.92 | 2025 | Orserdu |
| Amgen INC. | $15.72 | 2021 | |
| Boston Scientific Corporation | $15.61 | 2024 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amie Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.